Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
ABSTRACTCombination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1713707 |
| _version_ | 1797265876599177216 |
|---|---|
| author | Yubin Liu Wei Cao Ming Sun Taisheng Li |
| author_facet | Yubin Liu Wei Cao Ming Sun Taisheng Li |
| author_sort | Yubin Liu |
| collection | DOAJ |
| description | ABSTRACTCombination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advancing into clinical trials have shown certain efficacies in infected individuals. In addition, bNAbs have the potential to kill HIV-1-infected cells and to affect the course of HIV-1 infection by directly engaging host immunity. Nonetheless, challenges accompany the use of bNAbs, including transient suppression of viraemia, frequent emergence of resistant viruses in rebound viraemia, suboptimal efficacy in virus cell-to-cell transmission, and unclear effects on the cell-associated HIV-1 reservoir. In this review, we discuss opportunities and potential strategies to address current challenges to promote the future use of immunotherapy regimens. |
| first_indexed | 2024-03-07T17:24:05Z |
| format | Article |
| id | doaj.art-7cf07b6fddf34f5bba92799860ec78c1 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-04-25T00:51:46Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-7cf07b6fddf34f5bba92799860ec78c12024-03-11T16:04:24ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-019119420610.1080/22221751.2020.1713707Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunitiesYubin Liu0Wei Cao1Ming Sun2Taisheng Li3Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaDepartment of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, People’s Republic of ChinaDepartment of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaABSTRACTCombination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advancing into clinical trials have shown certain efficacies in infected individuals. In addition, bNAbs have the potential to kill HIV-1-infected cells and to affect the course of HIV-1 infection by directly engaging host immunity. Nonetheless, challenges accompany the use of bNAbs, including transient suppression of viraemia, frequent emergence of resistant viruses in rebound viraemia, suboptimal efficacy in virus cell-to-cell transmission, and unclear effects on the cell-associated HIV-1 reservoir. In this review, we discuss opportunities and potential strategies to address current challenges to promote the future use of immunotherapy regimens.https://www.tandfonline.com/doi/10.1080/22221751.2020.1713707HIV-1broadly neutralizing antibodies (bNAbs)efficacieschallengesopportunities |
| spellingShingle | Yubin Liu Wei Cao Ming Sun Taisheng Li Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities Emerging Microbes and Infections HIV-1 broadly neutralizing antibodies (bNAbs) efficacies challenges opportunities |
| title | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| title_full | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| title_fullStr | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| title_full_unstemmed | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| title_short | Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities |
| title_sort | broadly neutralizing antibodies for hiv 1 efficacies challenges and opportunities |
| topic | HIV-1 broadly neutralizing antibodies (bNAbs) efficacies challenges opportunities |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1713707 |
| work_keys_str_mv | AT yubinliu broadlyneutralizingantibodiesforhiv1efficacieschallengesandopportunities AT weicao broadlyneutralizingantibodiesforhiv1efficacieschallengesandopportunities AT mingsun broadlyneutralizingantibodiesforhiv1efficacieschallengesandopportunities AT taishengli broadlyneutralizingantibodiesforhiv1efficacieschallengesandopportunities |